- Ripple reaches a settlement with the SEC, reducing its penalty for XRP institutional sales to $50 million.
- Ripple invests $50 million in Wellgistics, enabling the use of XRP for real-time payments in U.S. pharmacy logistics.
- Politico reports controversy over a lobbying firm’s role in a social media post associating XRP with a proposed U.S. crypto reserve.
Ripple, the company behind the XRP digital asset, finalized a legal settlement with the U.S. Securities and Exchange Commission (SEC) this week. The SEC, which initially claimed Ripple’s XRP token was sold as an unregistered security, agreed to end litigation and reduce Ripple’s fine from $125 million to $50 million.
Both parties have dropped their appeals, as detailed in an official SEC announcement. The SEC clarified that this agreement does not signal its stance on other ongoing cases. The court had previously ruled that Ripple’s XRP sales to institutional investors were unregistered securities transactions, while sales on exchanges to regular investors were not.
Separately, Ripple announced a $50 million equity line of credit for the pharmaceutical logistics company Wellgistics. According to the release, this funding is structured as a loan backed by company assets. Wellgistics will use XRP for real-time payments and as part of its treasury operations in U.S. pharmacy supply chains. The initial news led to a sharp increase in Wellgistics’ stock price, but shares later dropped to $3, more than a third below pre-announcement levels.
Wellgistics CEO Brian Norton said in a statement, “We are developing a platform that connects manufacturers directly to pharmacies and patients – bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that’s long been starved of all three.”
Meanwhile, Politico reported that President Trump expressed displeasure with lobbyist Brian Ballard after a staff member persuaded him to announce a Crypto Strategic Reserve on social media. The post originally listed XRP, Solana (SOL), and Cardano (ADA) as reserve assets, omitting more established cryptocurrencies like Bitcoin and ether. When Trump learned of the lobbyist’s connection to Ripple, he reportedly directed a follow-up post, this time including bitcoin and ether as part of the reserve.
The use of digital assets in U.S. domestic payments remains rare. Wellgistics’ decision to use XRP for pharmacy payments drew questions, as traditional payment systems like ACH transfers typically cost much less per transaction than wire transfers. The company says its new blockchain-based platform aims to streamline health sector payments by increasing speed and transparency.
The healthcare and pharmaceutical sectors have been early adopters of blockchain, with firms like IBM, Mediledger, and LedgerDomain active in promoting data transparency and secure logistics. New laws now require more transparency and better data sharing between drug manufacturers, distributors, and pharmacies, facilitating blockchain adoption. Ripple expects its new partnership to encourage broader use of the XRP Ledger and, possibly, wider acceptance of XRP as a payment tool in non-financial industries.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
Previous Articles:
- Trump’s XRP Endorsement Sparks $44B Surge After Lobby Effort
- Ethereum Soars 28% After Ambitious Pectra Upgrade, Hits $2,400
- Radix Opens Token Holder Consultation on 2.4B XRD Reserve Plan
- Bitcoin Jumps 4.63% to $103,818; Ethereum Surges 23.14%
- Xangle Joins Theta Network as Enterprise Validator, Stakes 200K THETA
